U.S. market Closed. Opens in 2 days 4 hours 3 minutes

APLT | Applied Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.45 - 4.60
52 Week Range 1.1800 - 9.39
Beta 2.42
Implied Volatility 193.64%
IV Rank 36.74%
Day's Volume 2,055,149
Average Volume 798,050
Shares Outstanding 114,267,000
Market Cap 519,914,850
Sector Healthcare
Industry Biotechnology
IPO Date 2019-05-14
P/E Ratio -2.38
Forward P/E Ratio N/A
EPS -1.91
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 26
Country USA
Website APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
*Chart delayed
Analyzing fundamentals for APLT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see APLT Fundamentals page.

Watching at APLT technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on APLT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙